Related Experiment Video
Updated: Dec 26, 2025
07:15
Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation
Published on: January 16, 2019
11.3K
Automated Decision Support for Drug-Induced Long QT
Roxana A Lupu1, Heidi Twedt2, Sreekanth Chavour2
1Department of Internal Medicine, University of South Dakota Sanford School of Medicine.
Summary
Clinical informatics and genomics advance medicine. Decision support integrating EKG data is needed to manage drug-induced QT prolongation, which can occur without genetic abnormalities.
Area of Science:
- Clinical informatics
- Translational genomics
- Pharmacogenomics
Background:
- Automated decision support aids in managing drug-drug interactions to prevent QT prolongation.
- Drug-induced QT prolongation is a significant adverse drug reaction.
- Genetic variability can influence QT prolongation, but it can also occur without known genetic causes.
Purpose of the Study:
- To review the differences between congenital and drug-induced long QT syndrome.
- To highlight the need for advanced decision support systems in managing drug-induced QT prolongation.
Main Methods:
- Literature review comparing congenital long QT syndrome and drug-induced long QT syndrome.
- Analysis of current decision support systems in clinical informatics.
Main Results:
- Drug-induced QT prolongation can manifest without identifiable ion channel gene mutations.
- Distinguishing between congenital and acquired long QT syndromes is crucial for appropriate management.
Conclusions:
- Decision support tools must integrate electrocardiogram (EKG) data to effectively manage drug-induced QT prolongation.
- Personalized medicine approaches are evolving to address adverse drug reactions influenced by genetic and non-genetic factors.
More Related Videos
Related Concept Videos
01:12Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
1.7K
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
1.7K
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
2.6K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
2.6K
01:20Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
1.4K
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
1.4K
01:29Therapeutic Drug Monitoring: Affecting Factors
135
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
135
01:16Therapeutic Drug Monitoring: Overview and Classification
210
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...
210
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
1.3K
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
1.3K